Low-Dose Daunorubicin in Relapsed/Refractory Acute Leukemia
Status:
Active, not recruiting
Trial end date:
2021-11-01
Target enrollment:
Participant gender:
Summary
In this pilot study, eligible patients will be treated with 5 days of low dose daunorubicin
for one cycle only. Any patient who receives treatment on this protocol will be evaluable for
toxicity. Each patient will be assessed for the development of toxicity at all scheduled
visits (Days 1-5). Following participation on this brief pharmacodynamic trial, patients can
then proceed to other conventional or investigational therapies, as clinically indicated.